Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial

Rajeka Lazarus, Christian Taucher, Claire Brown, Irena Corbic, Leon Danon, Katrin Dubischar, Christopher J.A. Duncan, Susanne Eder-Lingelbach, Saul N Faust, Christopher Green, Karishma Gokani, Romana Hochreiter, Johanna Kellett Wright, Dowan Kwon, Alexander Middleditch, Alasdair P.S. Munro, Kush Naker, Florentina Penciu, David Price, Benedicte Querton, Tawassal Riaz, Amy Ross-Russell, Amada Sanchez-Gonzalez, Hayley Wardle, Sarah Warren, Adam Finn, the Valneva Phase 1 Trial Group
doi: https://doi.org/10.1101/2021.08.13.21262021

Data Availability

Data available on request

Back to top
Posted August 20, 2021.
Download PDF
Data/Code
Email
Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial
Rajeka Lazarus, Christian Taucher, Claire Brown, Irena Corbic, Leon Danon, Katrin Dubischar, Christopher J.A. Duncan, Susanne Eder-Lingelbach, Saul N Faust, Christopher Green, Karishma Gokani, Romana Hochreiter, Johanna Kellett Wright, Dowan Kwon, Alexander Middleditch, Alasdair P.S. Munro, Kush Naker, Florentina Penciu, David Price, Benedicte Querton, Tawassal Riaz, Amy Ross-Russell, Amada Sanchez-Gonzalez, Hayley Wardle, Sarah Warren, Adam Finn, the Valneva Phase 1 Trial Group
medRxiv 2021.08.13.21262021; doi: https://doi.org/10.1101/2021.08.13.21262021
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area